

Mathematical modelling of COVID-19 transmission dynamics with vaccination: A case study in Ethiopia

Sileshi Sintayehu Sharbayta¹, Henok Desalegn¹ and Tadesse Abdi¹

¹ Department of Mathematics, Addis Ababa University,
Addis Ababa, Ethiopia

Correspondence should be addressed to Sileshi Sintayehu Sharbayta ; sileshi.sintayehu@aau.edu.et

Abstract

In this paper, we consider a mathematical model of COVID-19 transmission with vaccination where the total population was subdivided into nine disjoint compartments, namely, Susceptible(S), Vaccinated with the first dose(V_1), Vaccinated with the second dose(V_2), Exposed (E), Asymptomatic infectious (I), Symptomatic infectious (I), Quarantine (Q), Hospitalized (H) and Recovered (R). We computed a reproduction parameter, R_v , using the next generation matrix. Analytical and numerical approach is used to investigate the results. In the analytical study of the model: we showed the local and global stability of disease-free equilibrium, the existence of the endemic equilibrium and its local stability, positivity of the solution, invariant region of the solution, transcritical bifurcation of equilibrium and conducted sensitivity analysis of the model. From these analysis, we found that the disease-free equilibrium is globally asymptotically stable for $R_v < 1$ and unstable for $R_v > 1$. A locally stable endemic equilibrium exists for $R_v > 1$, which shows persistence of the disease if the reproduction parameter is greater than unity. The model is fitted to cumulative daily infected cases and vaccinated individuals data of Ethiopia from May 01, 2021 to January 31, 2022. The unknown parameters are estimated using the least square method with built-in MATLAB function 'lsqcurvefit'. Finally, we performed different simulations using MATLAB and predicted the vaccine dose that will be administered at the end of two years. From the simulation results, we found that it is important to reduce the transmission rate, infectivity factor of asymptomatic cases and increase the vaccination rate, quarantine rate to control the disease transmission. Predictions show that the vaccination rate has to be increased from the current rate to achieve a reasonable vaccination coverage in the next two years.

Keywords: COVID-19, Vaccination, Control reproduction number, Sensitivity analysis, Endemic equilibrium, Parameter estimation.

1. Introduction

Corona Virus (COVID-19) is an infectious disease caused by a novel corona virus which is a respiratory illness that can spread in a population in several different ways. A person can be infected when droplets containing the virus are inhaled or come directly into contact with the eyes, nose, or mouth. The novel corona virus has been spreading worldwide starting from the first identification in December 2019. The world health organization (WHO) declared COVID-19 as a pandemic on march 12, 2020. Starting from the first day of the outbreak to March 9, 2022, more than 446.5 million confirmed cases and more than 6 million confirmed deaths are registered worldwide [25]. The same report shows 469007 confirmed cases and 7,476 confirmed deaths in the same period of time in Ethiopia.

The world is struggling to control the pandemic by imposing different restrictions based on country-specific strategies. Besides the restrictions, nowadays different countries are delivering vaccines for their people. As of day 7 March 2022, 10 vaccines were granted for emergency use by WHO [24]. These are Novavax, COVOVAX, Moderna, Pfizer/BioNTech, Janssen (Johnson & Johnson), AstraZeneca, Covishield (Oxford/AstraZeneca formulation), Covaxin, Sinopharm and Sinovac. Country approvals of this vaccine

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

38 differ. For example, Pfizer/BioNTech and Oxford/AstraZeneca are approved by 138 countries, Janssen
39 (Johnson & Johnson) is approved by 107, and Moderna is approved by 85 countries worldwide [24]. Until
40 March 07, 2022, about 10.9 billion COVID-19 vaccine doses are administered globally. 63.4% of the world
41 population has received at least one dose of a COVID-19 vaccine and this coverage represents developed
42 countries due to the scarcity of the vaccine in low-income countries. Only 13.6% of people in low-income
43 countries have received at least one dose [21]. Up to 5 March 2022, a total of 26,178,996 vaccine doses have
44 been administered in Ethiopia [25].

45
46 Studies involving mathematical models of infectious disease are helping the public health authorities by
47 giving insight information through analysis of the dynamics of the disease to make information- based
48 decisions and policy making. These studies are also powerful tools in predicting the future severity of a
49 disease. As far as COVID-19 is concerned, currently there are several such researches which have been
50 conducted and helping the struggle to contain the spread.

51
52 Before vaccines are produced, mathematical models for COVID-19 are focused on assessing the impacts of
53 nonpharmaceutical interventions(NPIs) like social distancing, wearing masks, personal hygiene, partial or
54 full lockdown and the like as control strategies. Here we mention some of them: [20, 1, 23, 2, 18, 13, 3]. In
55 [1], the authors studied the population level impact of implementation of behavioural change control
56 measures , the time horizon necessary to reduce the effective contact rate, and the proportion of people
57 under sanitary emergency measures in controlling COVID-19 in Mexico. One of the nonpharmaceutical
58 measures is to wear a face mask, and the quality of the face mask is sometimes debatable, but the study in
59 [13] suggested that broad adaption of even relatively ineffective face masks may significantly reduces the
60 transmission and hospitalization peak and death. For combating COVID-19, the timing of relaxation or
61 termination of nonpharmaceutical measures is essential. From this point of view, the authors in [18] showed
62 the crucial importance of relaxation or termination of strict social distancing measures in determining the
63 future burden of COVID-19 pandemic. In [3], they evaluate and compare the effectiveness of the four types
64 of NPIs of COVID-19, namely: the implementation of mandatory mask, quarantine or isolation, distancing
65 and traffic restriction in 190 countries between 23 January up to 13 April 2020. In their study, they
66 indicated that NPIs can significantly hold the COVID-19 pandemic. Distancing and the implementation of
67 two or more NPIs should be the priority strategies for holding COVID-19.

68
69 Currently, vaccines are available as one of and main control strategies. Epidemiological modelers started to
70 incorporate this additional intervention to see the dynamical properties of the disease and sort out some
71 important policy directions to the public health authorities. In this aspect, there are a number of studies,
72 from which [9, 17, 5] can be mentioned. A mathematical model with comorbidity and an optimal
73 control-based framework to decrease COVID-19 was studied in [9]. In this study, the authors found that an
74 optimal strategy with combined measures provide effective protection of the population from COVID-19
75 with minimum social and economic costs. Even during vaccination nonpharmaceutical interventions are
76 essential and it is shown that relaxing restrictions would cause benefits from vaccination to be lost by
77 increasing case numbers in which vaccination alone is insufficient to contain the outbreak [17]. Another
78 problem in attaining herd immunity in the population is vaccine hesitancy in case vaccination is not
79 mandatory, in which people are the last to decide either to get vaccinated or not. A behavioural modelling
80 approach was used to assess the impact of hesitancy and refusal of vaccine on the dynamics of the
81 COVID-19 [5]. In this paper, the authors showed hesitancy and refusal of vaccination is better contained in
82 case of large information coverage and small memory characteristics.

83
84 Some Epidemiological modelling studies of COVID-19 are based on country-specific data. Here we mention
85 few of the studies on COVID-19 modelling in the case of Ethiopia. In [16], the authors considered a
86 mathematical model for the transmission dynamics of COVID-19 by incorporating self-protection behavior
87 changes in the population. Based on the available data of Ethiopia and other countries, they estimated the
88 unknown parameter values using a combination of least squares and Bayesian estimation methods. They

89 found that the sensitive parameters for the spread of the virus vary from country to country and control of
90 the effective transmission rate (recommended human behavioral change towards self-protective measures) is
91 essential to stop the spread of the virus. A mathematical model of COVID-19 in the case of Ethiopia is also
92 considered in [15], and in the study they found that the spread of COVID-19 can be managed by minimizing
93 the contact rate of infected and increasing the quarantine of exposed individuals. There are also other
94 COVID-19 mathematical modelling for optimal control and assessing the impact of nonpharmaceutical
95 interventions on the dynamics of COVID-19 which are specific to Ethiopian data [10, 14]. We believe that
96 scientific studies on COVID-19 transmission in the case of Ethiopia are limited and as far as we review there
97 are no mathematical modelling studies considering the current situation (including vaccination). Therefore,
98 in our study we consider a mathematical model of COVID-19 transmission dynamics with vaccination.

99 The paper is organized as follows: In Section (2), we describe the model and formulation of the differential
100 equation. In Section (3), we carry out the mathematical analysis of the model. Section (4) is devoted
101 to numerical simulation and discussion. In Section (5), we present a prediction of the cumulative vaccine
102 administered with respect to the first dose vaccination rate. Finally, in Section (6), the conclusion is presented.

103 2. Model description and formulation

104 In this study, we proposed a model where the total population is divided into nine compartments. Namely
105 Susceptible, Vaccinated with first dose, vaccinated with second dose, Exposed (Infected but not yet infectious),
106 Asymptomatic infectious, Symptomatic infectious, Quarantine, Hospitalized and Recovered denoted by S , V_1 ,
107 V_2 , E , I_a , I_s , Q , H and R respectively. We assumed that individuals in Q and H class are isolated from
108 the population and therefore they will have a negligible role in transmitting the disease. Therefore, only
109 individuals in I_a and I_s are capable of transmitting the disease. Vaccines available for COVID-19 do not
110 totally prevent infection, therefore individuals in S , V_1 and V_2 class can get infected with the force of infection
111 $h = \beta \frac{\tau I_a + I_s}{N - (Q + H)}$. Such a force of infection is used in most COVID-19 models [15, 10, 4], where β is the
112 transmission rate, τ is the infectivity factor of asymptomatic individuals and N is the total population. Due
113 to the vaccine efficacy, individuals in V_1 and V_2 class are relatively less infected than the fully susceptible ones:
114 they will get infected with reduced vulnerability of $(1 - \eta_1)$ and $(1 - \eta_2)$ respectively. η_1 measures the efficacy
115 of the first dose vaccine, where as η_2 measures the efficacy after the second dose. Majority of the vaccines
116 approved by WHO are given in two doses with an average recommended time interval between the two doses.
117 We considered this scenario in our model. Susceptible individuals get vaccination (the first dose) at the rate
118 of p_1 and those who got the first dose will get the second dose after an average $1/\alpha$ period of time with the
119 rate p_2 . In this study we did not fix a particular vaccine type therefore the value of $1/\alpha$ represents the average
120 time needed to take the second dose. ρ proportion of exposed individuals will move to asymptomatic class
121 and the rest, $(1 - \rho)$ proportion will move to the symptomatic class after they finish the incubation period
122 of $\frac{1}{e}$ day, where e is the infection rate. Mostly the symptoms of COVID-19 are similar to other respiratory
123 diseases like common cold and flu, so all symptomatic individuals do not quarantine. Those only tested
124 and confirmed can go to quarantine. Symptomatic individuals get tested and quarantine at the rate of δ .
125 Those quarantined may develop serious illness, in this case they go to hospital at the rate of q_h . Individuals
126 in I_a , I_s , Q and H will recover from the disease at the rate of r_a , r_s , r_q and r_h respectively. Asymptomatic
127 are individuals with less pain and assumed will not die due to the disease. As a consequence, individuals in
128 I_s , Q and H classes die due to the disease at the rate of d (assumed to be equal). People in all compartments
129 will die naturally at the rate of μ and π is the recruitment rate to the susceptible compartment. The total
130 population size at time t is denoted by $N(t)$ where,

$$N(t) = S(t) + V_1(t) + V_2(t) + E(t) + I_a(t) + I_s(t) + Q(t) + H(t) + R(t). \quad (1)$$

131 The model flow diagram is shown in Figure 1.




Figure 1: Disease transmission diagram: green compartment indicates non-infected, the red compartment is infected and infectious and the yellow compartment shows infected but assumed to be not infectious (Q and H), on incubation period (H).

132 From the schematic diagram Figure(1) the following system of differential equation is obtained

$$\begin{cases} \frac{dS}{dt} = \pi - (p_1 + \mu + h)S \\ \frac{dV_1}{dt} = p_1S - (\alpha p_2 + \mu + (1 - \eta_1)h)V_1 \\ \frac{dV_2}{dt} = \alpha p_2V_1 - (\mu + (1 - \eta_2)h)V_2 \\ \frac{dE}{dt} = (S + (1 - \eta_1)V_1 + (1 - \eta_2)V_2)h - (\mu + e)E \\ \frac{dI_a}{dt} = \rho eE - (\mu + r_a)I_a \\ \frac{dI_s}{dt} = (1 - \rho)eE - (r_s + \mu + d + \delta)I_s \\ \frac{dQ}{dt} = \delta I_s - (\mu + d + q_h + r_q)Q \\ \frac{dH}{dt} = q_h Q - (\mu + d + r_h)H \\ \frac{dR}{dt} = r_a I_a + r_s I_s + r_q Q + r_h H - \mu R, \end{cases} \quad (2)$$

133 with initial conditions

134

135 $S(0) \geq 0, V_1(0) \geq 0, V_2(0) \geq 0, E(0) \geq 0, I_a(0) \geq 0, I_s(0) \geq 0, Q(0) \geq 0, H(0) \geq 0$ and $R(0) \geq 0$.

136 3. Model analysis

137 In this section, positivity of solution, the invariant region, disease-free equilibrium, reproduction number,
138 stability analysis, endemic equilibrium point, bifurcation and sensitivity analysis are discussed.

139 3.1 Positivity and boundedness of the solutions

140 Since each component of the given model system considers a human population, it is necessary to show that
141 all variables $S(t), V_1(t), V_2(t), E(t), I_a(t), I_s(t), Q(t), H(t)$ and $R(t)$ are positive for all $t > 0$.

142 **Theorem 3.1.1.** *If $S(0) \geq 0$, $V_1(0) \geq 0$, $V_2(0) \geq 0$, $E(0) \geq 0$, $I_a(0) \geq 0$, $I_s(0) \geq 0$, $Q(0) \geq 0$, $H(0) \geq 0$ and*
 143 *$R(0) \geq 0$, then the solution set $\{S(t), V_1(t), V_2(t), E(t), I_a(t), I_s(t), Q(t), H(t), R(t)\}$ of the model (2) consists*
 144 *of positive members for all $t > 0$.*

Proof. From the first equation of system (2), we have

$$\frac{dS}{dt} = \pi - (p_1 + \mu + h)S.$$

This leads to,

$$\frac{dS}{dt} \geq -(p_1 + \mu + h)S.$$

And hence,

$$\frac{dS}{S} \geq -(p_1 + \mu + h)dt,$$

Upon integration, we obtain,

$$S(t) \geq S(0) \exp\left(-\int_0^t (p_1 + \mu + h)du\right) \geq 0,$$

145 Thus, $S(t) \geq 0$.

146

147 Similarly, it can be shown that the other equations of system (2) are positive for all $t > 0$. Hence, the state
 148 variables of the system are all positive for all $t > 0$. \square

149 **Theorem 3.1.2.** *The feasible solution set $\{S, V_1, V_2, E, I_a, I_s, Q, H, R\}$ of the model (2) with the given initial*
 150 *condition remains bounded in the region $\Omega = \{(S, V_1, V_2, E, I_a, I_s, Q, H, R) \in \mathbb{R}_+^9 : 0 \leq N \leq \frac{\pi}{\mu}\}$.*

151 *Proof.* Differentiating N in equation (1) with respect to t we obtain;

$$\frac{dN}{dt} = \frac{dS}{dt} + \frac{dV_1}{dt} + \frac{dV_2}{dt} + \frac{dE}{dt} + \frac{dI_a}{dt} + \frac{dI_s}{dt} + \frac{dQ}{dt} + \frac{dH}{dt} + \frac{dR}{dt}. \quad (3)$$

Using system (2) and evaluating at (3) gives us;

$$\frac{dN}{dt} = \pi - \mu N - d(I_s + Q) - H(\mu + d).$$

152 Since the state variables of system I_s, Q and H are positive for all $t \geq 0$ we have

$$\frac{dN}{dt} \leq \pi - \mu N, \quad (4)$$

in which N is asymptotically bounded

$$i.e. \quad 0 \leq N \leq \frac{\pi}{\mu}.$$

153 This completes the proof. \square

154 3.2 Reproduction number, existence and stability analysis of equilibria

155 3.2.1 Disease-free equilibrium point

156 In this subsection, we determine the equilibrium point at which there is no disease in the population (i.e.
157 $I_a = I_s = Q = H = E = R = 0$) by letting the right hand side of system (2) to zero. We get:

$$E_{dfe} = (S^*, V_1^*, V_2^*, E^*, I_a^*, I_s^*, Q^*, H^*, R^*),$$

$$= \left(\frac{\pi}{p_1 + \mu}, \frac{p_1 \pi}{(p_1 + \mu)(\mu + \alpha p_2)}, \frac{\pi \alpha p_1 p_2}{\mu(p_1 + \mu)(\mu + \alpha p_2)}, 0, 0, 0, 0, 0, 0 \right). \quad (5)$$

158 **Remark 1.** In (5), when there is no vaccination, i.e., $p_1 = 0$, the disease-free equilibrium will be reduced to
159 a fully susceptible disease-free state given by

$$E_0 = (S^*, V_1^*, V_2^*, E^*, I_a^*, I_s^*, Q^*, H^*, R^*),$$

$$= \left(\frac{\pi}{\mu}, 0, 0, 0, 0, 0, 0, 0, 0 \right). \quad (6)$$

160 If $p_1 = 1$ we get a disease-free equilibrium in which every susceptible individual is vaccinated with the first
161 dose, which can be expressed by

$$E_{01} = (S^*, V_1^*, V_2^*, E^*, I_a^*, I_s^*, Q^*, H^*, R^*),$$

$$= \left(\frac{\pi}{1 + \mu}, \frac{\pi}{(1 + \mu)(\mu + \alpha)}, \frac{\pi \alpha}{\mu(1 + \mu)(\mu + \alpha)}, 0, 0, 0, 0, 0, 0 \right). \quad (7)$$

162 3.2.2 Reproduction number

163 The basic reproduction number (R_0) is the average number of secondary cases produced by one primary
164 infection during the infectious period in a fully susceptible population and the control reproduction number
165 (in our case denoted by R_v) is used to represent the same quantity for a system incorporating control (or
166 intervention) strategies [12]. We will use the next generation matrix method [11] to find the basic and control
167 reproduction number.

168 Let the matrix for new infection appearance at the infected compartment be given by \mathcal{F} ,

$$\mathcal{F} = \begin{bmatrix} E \\ I_a \\ I_s \\ Q \\ H \end{bmatrix} \begin{bmatrix} (S + (1 - \eta_1)V_1 + (1 - \eta_2)V_2)h \\ 0 \\ 0 \\ 0 \\ 0 \end{bmatrix}, \quad (8)$$

169 and the matrix of other transactions at each of the infected compartments can be represented by \mathcal{V} , and is
170 given by

$$\mathcal{V} = \begin{bmatrix} E \\ I_a \\ I_s \\ Q \\ H \end{bmatrix} = \begin{bmatrix} (\mu + e)E \\ (\mu + r_a)I_a - \rho eE \\ (r_s + \mu + d + \delta)I_s - (1 - \rho)eE \\ (\mu + d + r_h + r_a)Q - \delta I_s \\ (\mu + d + r_h)H - q_h Q \end{bmatrix}. \quad (9)$$

171 Now finding the Jacobian of \mathcal{F} and \mathcal{V} , we get matrices F (only the first row, nonzero row) and V written as;

$$F = \begin{bmatrix} 0 & (S + (1 - \eta_1)V_1 + (1 - \eta_2)V_2) \frac{\partial h}{\partial I_a} & (S + (1 - \eta_1)V_1 + (1 - \eta_2)V_2) \frac{\partial h}{\partial I_s} & 0 & 0 \end{bmatrix}, \quad (10)$$

where,

$$\frac{\partial h}{\partial I_a} = \frac{\beta\tau(N - (Q + H)) - \beta(\tau I_a + I_s)}{(N - (Q + H))^2} \quad (11)$$

$$\frac{\partial h}{\partial I_s} = \frac{\beta(N - (Q + H)) - \beta(\tau I_a + I_s)}{(N - (Q + H))^2} \quad (12)$$

172 and

$$V = \begin{bmatrix} (\mu + e) & 0 & 0 & 0 & 0 \\ -\rho e & (\mu + r_a) & 0 & 0 & 0 \\ -(1 - \rho)e & 0 & (r_s + \mu + d + \delta) & 0 & 0 \\ 0 & 0 & -\delta & (\mu + d + r_h + r_a) & 0 \\ 0 & 0 & 0 & -q_h & (\mu + d + r_h) \end{bmatrix}. \quad (13)$$

The control reproduction number is given by $R_v = \nu(F(E_v) \times V^{-1})$. Where ν is the spectral radius of the matrix $F(E_v) \times V^{-1}$. Thus R_v , can be written as:

$$R_v = \frac{(\mu(\mu + \alpha p_2) + (1 - \eta_1)p_1\mu + (1 - \eta_2)\alpha p_1 p_2)}{(\mu + e)(\mu + p_1)(\mu + \alpha p_2)} \left(\frac{\rho e \beta \tau}{\mu + r_a} + \frac{(1 - \rho)e\beta}{r_s + \mu + d + \delta} \right). \quad (14)$$

173 The basic reproduction number, R_0 is obtained by setting $p_1 = p_2 = 0$ in (14) and is given by:

$$R_0 = \frac{\rho e \beta \tau}{(\mu + e)(\mu + r_a)} + \frac{(1 - \rho)e\beta}{(\mu + e)(\mu + r_s + d + \delta)}. \quad (15)$$

174 We can rewrite equation (14) in terms of R_0 as;

$$R_v = \left(\frac{\mu(\mu + \alpha p_2) + (1 - \eta_1)p_1\mu + (1 - \eta_2)\alpha p_1 p_2}{(p_1 + \mu)(\mu + \alpha p_2)} \right) R_0. \quad (16)$$

175 **Remark 2.** If $\eta_1 = \eta_2 = 0$, then $R_v = R_0$. Otherwise ($0 < \eta_1, \eta_2 \leq 1$) $R_v < R_0$.

176 In system (2), the solution for the state variables Q, H and R can easily be solved from other variables in
177 the system and they does not affect them, therefore in the following subsections we restrict our mathematical
178 analysis to the following system of equations.

$$\begin{cases} \frac{dS}{dt} = \pi - (p_1 + \mu + h)S \\ \frac{dV_1}{dt} = p_1 S - (\alpha p_2 + \mu + (1 - \eta_1)h)V_1 \\ \frac{dV_2}{dt} = \alpha p_2 V_1 - (\mu + (1 - \eta_2)h)V_2 \\ \frac{dE}{dt} = (S + (1 - \eta_1)V_1 + (1 - \eta_2)V_2)h - (\mu + e)E \\ \frac{dI_a}{dt} = \rho e E - (\mu + r_a)I_a \\ \frac{dI_s}{dt} = (1 - \rho)e E - (r_s + \mu + d + \delta)I_s \end{cases} \quad (17)$$

179 3.2.3 Local stability of disease-free equilibrium

180 **Theorem 3.2.1.** The disease-free equilibrium, E_{df_e} is locally asymptotically stable if $R_v < 1$ and unstable if
181 $R_v > 1$.

182 *Proof.* The Jacobian matrix of the system (17) is given by:

$$J = \begin{bmatrix} -(p_1 + \mu + h) & 0 & 0 & 0 & -\frac{\partial h}{\partial I_a} S & -\frac{\partial h}{\partial I_s} S \\ p_1 & -(\mu + \alpha p_2 + (1 - \eta_1)h) & 0 & 0 & -(1 - \eta_1)V_1 \frac{\partial h}{\partial I_a} & -(1 - \eta_1)V_1 \frac{\partial h}{\partial I_s} \\ 0 & \alpha p_2 & -(\mu + (1 - \eta_2)h) & 0 & -(1 - \eta_2)V_2 \frac{\partial h}{\partial I_a} & -(1 - \eta_2)V_2 \frac{\partial h}{\partial I_s} \\ h & (1 - \eta_1)h & (1 - \eta_2)h & -(\mu + e) & H_1 & H_2 \\ 0 & 0 & 0 & \rho e & -(\mu + r_a) & 0 \\ 0 & 0 & 0 & (1 - \rho)e & 0 & -(r_s + \mu + d + \delta) \end{bmatrix}, \quad (18)$$

where

$$H_1 = \frac{\partial h}{\partial I_a} \times (S + (1 - \eta_1)V_1 + (1 - \eta_2)V_2)$$

$$H_2 = \frac{\partial h}{\partial I_s} \times (S + (1 - \eta_1)V_1 + (1 - \eta_2)V_2),$$

183 and $\frac{\partial h}{\partial I_a}$ and $\frac{\partial h}{\partial I_s}$ are as in equations (11) and (12).

184 The Jacobian matrix (18) evaluated at the disease-free equilibrium E_v is given by:

$$J(E_v) = \begin{bmatrix} -(\mu + p_1) & 0 & 0 & 0 & \frac{\partial h}{\partial I_a}(E_v)S^* & \frac{\partial h}{\partial I_s}(E_v)S^* \\ p_1 & -(\mu + \alpha p_2) & 0 & 0 & -(1 - \eta_1)\frac{\partial h}{\partial I_a}(E_v)V_1^* & -(1 - \eta_1)\frac{\partial h}{\partial I_s}(E_v)V_1^* \\ 0 & \alpha p_2 & -\mu & 0 & -(1 - \eta_2)\frac{\partial h}{\partial I_a}(E_v)V_2^* & -(1 - \eta_2)\frac{\partial h}{\partial I_s}(E_v)V_2^* \\ 0 & 0 & 0 & -(\mu + e) & H_1^* & H_2^* \\ 0 & 0 & 0 & \rho e & -(\mu + r_a) & 0 \\ 0 & 0 & 0 & (1 - \rho)e & 0 & -(r_s + \mu + d + \delta) \end{bmatrix}, \quad (19)$$

where

$$\frac{\partial h}{\partial I_a}(E_v) = \frac{\beta \tau \mu (p_1 + \mu)(\mu + \alpha p_2)}{\mu \pi (\mu + \alpha p_2) + p_1 \pi \mu + \pi \alpha p_1 p_2}$$

$$\frac{\partial h}{\partial I_s}(E_v) = \frac{\beta \mu (p_1 + \mu)(\mu + \alpha p_2)}{\mu \pi (\mu + \alpha p_2) + p_1 \pi \mu + \pi \alpha p_1 p_2}$$

$$H_1^* = \beta \tau \frac{\mu(\mu + \alpha p_2) + \mu(1 - \eta_1)p_1 + (1 - \eta_2)p_1 p_2 \alpha}{(p_1 + \mu)(\mu + \alpha p_2)}$$

$$H_2^* = \beta \frac{\mu(\mu + \alpha p_2) + \mu(1 - \eta_1)p_1 + (1 - \eta_2)p_1 p_2 \alpha}{(p_1 + \mu)(\mu + \alpha p_2)},$$

185 and its characteristic equation is:

$$((\mu + \lambda)(\mu + p_1 + \lambda)(\mu + \alpha p_2 + \lambda))(-\lambda^3 - B_1 \lambda^2 + B_2 \lambda + B_3) = 0, \quad (20)$$

where

$$B_1 = r_s + 3\mu + d + \delta + r_a + e,$$

$$B_2 = (1 - \rho)eH_2^* - (r_s + \mu + d + \delta)(2\mu + r_a + e) + \rho eH_1^* - (\mu + e)(\mu + r_a),$$

$$B_3 = (1 - \rho)e(\mu + r_a)H_2^* - (r_s + \mu + d + \delta)((\mu + e)(\mu + r_a) - \rho eH_1^*).$$

From (20) we have the roots given by $\lambda_1 = -\mu$, $\lambda_2 = -(\mu + \alpha p_2)$, $\lambda_3 = -(\mu + p_1)$ and $-\lambda^3 - B_1 \lambda^2 + B_2 \lambda + B_3 = 0$. By Descartes' rule of sign, the roots of the later equation will be negative if $B_2 < 0$ and $B_3 < 0$.

Let write the equation for R_v in (14) in terms of H_1^* and H_2^* as:

$$R_v = \frac{\rho e}{(\mu + r_a)(\mu + e)} H_1^* + \frac{(1 - \rho)e}{(\mu + r_s + d + \delta)(\mu + e)} H_2^*.$$

Suppose $R_v < 1$, which implies

$$\rho e(\mu + r_s + d + \delta)H_1^* + (1 - \rho)e(\mu + r_a)H_2^* < (\mu + e)(\mu + r_a)(\mu + r_s + d + \delta).$$

Therefore,

$$\rho e(\mu + r_s + d + \delta)H_1^* < (\mu + e)(\mu + r_a)(\mu + r_s + d + \delta),$$

and

$$(1 - \rho)e(\mu + r_a)H_2^* < (\mu + e)(\mu + r_a)(\mu + r_s + d + \delta) < (\mu + r_s + d + \delta)(\mu + r_a)(2\mu + r_a + e),$$

186 which are equivalently written as

$$\begin{aligned} \rho eH_1^* - (\mu + e)(\mu + r_a) &< 0 \\ (1 - \rho)eH_2^* - (\mu + e)(2\mu + r_a + e) &< 0. \end{aligned} \quad (21)$$

187 From the inequalities in (21), we summarize that: $B_2 < 0$ if $R_v < 1$. And it can also be shown that $B_3 < 0$
 188 whenever $R_v < 1$. Therefore, the disease-free equilibrium E_{df_e} is locally asymptotically stable if $R_v < 1$. For
 189 $R_v > 1$, B_2 will be greater than zero, therefore we will have at least one positive eigenvalue, therefore E_{df_e}
 190 will be unstable. \square

191 3.2.4 Global stability of disease-free equilibrium point when $R_v < 1$

To investigate the global stability of disease-free equilibrium, we use the technique implemented by Castillo-Chavez et al. [7]. We write the model system (17) as

$$\begin{aligned} \frac{dU}{dt} &= F(U, Z) \\ \frac{dZ}{dt} &= G(U, Z) \\ G(U, 0) &= 0 \end{aligned}$$

192 where U stands for the uninfected individual, that is, $U = (S, V_1, V_2)^T \in \mathbb{R}_+^3$ and Z for the infected individuals
 193 ,that is, $Z = (E, I_a, I_s)^T \in \mathbb{R}_+^3$. The disease free equilibrium point of the model is denoted by $E_v = (U_0, 0)$.
 194 For $R_v < 1$, for which the disease free equilibrium point is locally asymptotically stable the following two
 195 conditions are sufficient to guarantee the global stability of disease free equilibrium point $(U_0, 0)$.

196 (H1) For $\frac{du}{dt} = F(U, 0)$, U_0 is globally asymptotically stable.

197 (H2) $G(U, Z) = AZ - \tilde{G}(U, Z)$, where $\tilde{G}(U, Z) \geq 0$ for all $(U, Z) \in \Omega$

198 where $A = D_U G(U_0, 0)$ is a M-matrix (the off diagonal elements of A are nonnegative) and Ω is the region
 199 where the model makes biological sense.

200 **Theorem 3.2.2.** *The point $E_v = (U_0, 0)$ is globally asymptotically stable provided that $R_v < 1$ and the*
 201 *conditions expressed in (H1) and (H2) are satisfied.*

Proof. For condition (H1) from the system (17) we can get $F(U, Z)$

$$F(U, Z) = \begin{bmatrix} \pi - (p_1 + \mu + h)S \\ p_1 S - (\alpha p_2 + \mu + (1 - \eta_1)h)V_1 \\ \alpha p_2 V_1 - (\mu + (1 - \eta_2)h)V_2 \end{bmatrix}$$

Hence,

$$F(U, 0) = \begin{bmatrix} \pi - (p_1 + \mu)S \\ p_1 S - (\alpha p_2 + \mu)V_1 \\ \alpha p_2 V_1 - \mu V_2 \end{bmatrix}$$

202 It is obvious that $U_0 = (\frac{\pi}{p_1 + \mu}, \frac{p_1 \pi}{(p_1 + \mu)(\mu + \alpha p_2)}, \frac{\pi \alpha p_1 p_2}{\mu(p_1 + \mu)(\mu + \alpha p_2)}, 0)$ is globally asymptotically stable for $F(U, 0)$ as
 203 $U \rightarrow U_0$ when $t \rightarrow \infty$.

For condition (H2) from the system (17) we can get $G(U, Z)$

$$G(U, Z) = \begin{bmatrix} (S + (1 - \eta_1)V_1 + (1 - \eta_2)V_2)h - (\mu + e)E \\ \rho eE - (\mu + r_a)I_a \\ (1 - \rho)eE - (r_s + \mu + d + \delta)I_s \end{bmatrix}$$

and

$$A = \begin{bmatrix} -(\mu + e) & (S^* + (1 - \eta_1)V_1^* + (1 - \eta_2)V_2^*)\frac{\beta\tau}{N^*} & (S^* + (1 - \eta_1)V_1^* + (1 - \eta_2)V_2^*)\frac{\beta}{N^*} \\ e\rho & -(\mu + r_a) & 0 \\ (1 - \rho)e & 0 & -(r_s + \mu + d + \delta) \end{bmatrix}$$

where,

$$N^* = S^* + V_1^* + V_2^*$$

We have

$$\begin{aligned} \tilde{G}(U, Z) &= AZ - G(U, Z) \\ &= \begin{bmatrix} \tilde{G}_1(U, Z) \\ \tilde{G}_2(U, Z) \\ \tilde{G}_3(U, Z) \end{bmatrix} = \begin{bmatrix} \beta(\tau I_a + I_s) \left[\frac{S^* + (1 - \eta_1)V_1^* + (1 - \eta_2)V_2^*}{N^*} - \left(\frac{S + (1 - \eta_1)V_1 + (1 - \eta_2)V_2}{N - (Q + H)} \right) \right] \\ 0 \\ 0 \end{bmatrix} \end{aligned}$$

204 which leads to $\tilde{G}(U, Z) \geq 0$ for all $(U, Z) \in \Omega$. Hence both the conditions (H1) and (H2) are satisfied.
 205 Therefore, the disease-free equilibrium point is globally asymptotically stable for $R_v < 1$. \square

206 3.2.5 Existence of endemic equilibrium

207 By equating the system (2) to zero, we get the endemic equilibrium in terms of the force of infection h and
 208 we denote it by

$$209 E_{end} = (S^e, V_1^e, V_2^e, E^e, I_a^e, I_s^e, Q^e, H^e, R^e),$$

the components of E_{end} are given as follows:

$$\begin{aligned} S^e &= \frac{\pi}{p_1 + \mu + h^e}, \\ V_1^e &= \frac{p_1 \pi}{(p_1 + \mu + h^e)(\alpha p_2 + \mu + (1 - \eta_1)h^e)}, \\ V_2^e &= \frac{p_1 p_2 \alpha \pi}{(p_1 + \mu + h^e)(\alpha p_2 + \mu + (1 - \eta_1)h^e)(\mu + (1 - \eta_2)h^e)}, \\ E^e &= \frac{h^e \pi [(\mu + (1 - \eta_2)h^e)(\alpha p_2 + \mu + (1 - \eta_1)h^e) + p_1(1 - \eta_1)(\mu + (1 - \eta_2)h^e) + \alpha p_1 p_2(1 - \eta_2)]}{(\mu + e)(p_1 + \mu + h^e)(\alpha p_2 + \mu + (1 - \eta_1)h^e)(\mu + (1 - \eta_2)h^e)}, \\ I_a^e &= \frac{\rho e h^e \pi [(\mu + (1 - \eta_2)h^e)(\alpha p_2 + \mu + (1 - \eta_1)h^e) + p_1(1 - \eta_1)(\mu + (1 - \eta_2)h^e) + \alpha p_1 p_2(1 - \eta_2)]}{(\mu + r_a)(\mu + e)(p_1 + \mu + h^e)(\alpha p_2 + \mu + (1 - \eta_1)h^e)(\mu + (1 - \eta_2)h^e)}, \\ I_s^e &= \frac{(1 - \rho) e h^e \pi [(\mu + (1 - \eta_2)h^e)(\alpha p_2 + \mu + (1 - \eta_1)h^e) + p_1(1 - \eta_1)(\mu + (1 - \eta_2)h^e) + \alpha p_1 p_2(1 - \eta_2)]}{(r_s + \mu + d + \delta)(\mu + e)(p_1 + \mu + h^e)(\alpha p_2 + \mu + (1 - \eta_1)h^e)(\mu + (1 - \eta_2)h^e)}, \\ Q^e &= \frac{\delta}{\mu + d + q_h + r_q} \times I_s^e, \\ H^e &= \frac{q_h}{\mu + d + r_h} \times Q^e, \\ R^e &= \frac{r_a I_a^e + r_s I_s^e + r_q Q^e + r_h H^e}{\mu}, \end{aligned}$$

210 where h^e is the positive root of the equation

$$g(h^e) = A(h^e)^3 + B(h^e)^2 + Ch^e + D = 0, \quad (22)$$

obtained from

$$h^e = \frac{\beta(\tau I_a^e + I_s^e)}{(S^e + V_1^e + V_2^e + E^e + I_a^e + I_s^e + R^e)},$$

and the coefficients in equation (22) are given by

$$A = (1 - \eta_1)(1 - \eta_2)$$

$$B = \frac{J_1 + \left(\mu(\mu + \alpha p_2)(p_1 + \mu)(1 - \eta_1)(1 - \eta_2) \right)(1 - R_v)}{\mu(\mu + \alpha p_2) + (1 - \eta_1)p_1\mu + (1 - \eta_2)\alpha p_1 p_2}$$

$$C = \frac{J_2 + \left((p_1 + \mu)(\mu^2(1 - \eta_1)(\mu + \alpha p_2) + \mu(1 - \eta_2)(\mu + \alpha p_2)^2) + p_1\mu(1 - \eta_1)(\alpha p_2 + \mu)(p_1 + \mu)(1 - \eta_2) \right)(1 - R_v)}{\mu(\mu + \alpha p_2) + (1 - \eta_1)p_1\mu + (1 - \eta_2)\alpha p_1 p_2}$$

$$D = \mu(p_1 + \mu)(\alpha p_2 + \mu)(1 - R_v),$$

where,

$$\begin{aligned} J_1 &= \mu(\mu + \alpha p_2)(\mu(1 - \eta_1) + (\mu + \alpha p_2)(1 - \eta_2)) + p_1\mu(1 - \eta_1)^2(\mu + (p_1 + \mu)(1 - \eta_2) + (\alpha p_2 + \mu)) \\ &\quad + \alpha p_1 p_2(1 - \eta_2)(\mu(1 - \eta_1) + (p_1 + \mu)(1 - \eta_1)(1 - \eta_2) + (\alpha p_2 + \mu)(1 - \eta_2)) \\ J_2 &= \mu^2(\alpha p_2 + \mu)^2 + p_1\mu^2(1 - \eta_1)((p_1 + \mu)(1 - \eta_1) + (\alpha p_2 + \mu)) \\ &\quad + \mu\alpha p_1 p_2(1 - \eta_2)((1 - \eta_1)(p_1 + \mu) + (\alpha p_2 + \mu) + (\alpha p_2 + \mu)(p_1 + \mu)(1 - \eta_1)). \end{aligned}$$

211 It can easily be seen that $A > 0$. If $R_v > 1$ then $D < 0$, therefore $h(0) < 0$. Additionally $\lim_{h^e \rightarrow \infty} g(h^e) > 0$.
 212 Therefore, from the continuity of g , there exists at least one positive h_*^e such that $g(h_*^e) = 0$ and hence
 213 there will be at least one endemic equilibrium of the model system (2). On the other hand, if $R_v < 1$, then
 214 $B > 0, C > 0$ and $D > 0$ then by Descartes' rule of sign, (22) has no positive real root, which proves that
 215 there is no endemic equilibrium point when $R_v < 1$. From the above discussion, we can state the following
 216 theorem.

217 **Theorem 3.2.3.** *If $R_v > 1$, there exists at least one endemic equilibrium point for the model system (2) and*
 218 *there is no endemic equilibrium point for the model system (2) when $R_v < 1$.*

219 3.3 Bifurcation analysis

We determine the occurrence of a transcritical bifurcation at $R_v = 1$ by adopting the well-known approach based on the general center manifold theory [6]. In short, it establishes that the normal form representing the dynamics of the system on the central manifold is given by:

$$\dot{u} = au^2 + b\beta u,$$

220 where

$$a = \sum_{k,i,j=1}^n \nu_k \omega_i \omega_j \frac{\partial^2 f_k}{\partial x_i \partial x_j}(E_v, \beta^*), \quad (23)$$

221 and

$$b = \sum_{k,i=1}^n \nu_k \omega_i \frac{\partial^2 f_k}{\partial x_i \partial \beta}(E_v, \beta^*). \quad (24)$$

222 Note that β has been chosen as a bifurcation parameter and β^* is its critical value, f represents the right-hand
 223 side of the system (17), x represents the state variable vector, $x = (x_1, x_2, x_3, x_4, x_5, x_6) = (S, V_1, V_2, E, I_a, I_s)$,

224 ν and ω are the left and right eigenvectors corresponding to the zero eigenvalue of the Jacobian matrix at the
 225 disease-free equilibrium and the critical value, i.e., at E_v and $\beta = \beta^*$.

Observe that $R_v = 1$ is equivalent to $\beta = \beta^*$, with

$$\beta^* = \frac{(\mu + e)(\mu + p_1)(\mu + \alpha p_2)}{\mu(\mu + \alpha p_2) + (1 - \eta_1)p_1\mu + (1 - \eta_2)\alpha p_1 p_2} \times C,$$

where,

$$C = \frac{(\mu + r_a)(r_s + \mu + d + \delta)}{\rho e \tau (r_s + \mu + d + \delta) + (1 - \rho)e(\mu + r_a)}$$

Thus, according to Theorem 4.1[6], the disease-free equilibrium is locally asymptotically stable if $\beta < \beta^*$, and it is unstable when $\beta > \beta^*$. The direction of the bifurcation occurring at $\beta = \beta^*$ can be derived from the sign of the coefficients (23) and (24). More precisely, if $a > 0$ (resp. $a < 0$) and $b > 0$, then at $\beta = \beta^*$ there is a backward (resp. forward) bifurcation.

By evaluating the Jacobian matrix of system (17) at E_v and $\beta = \beta^*$, we get

$$J(E_v, \beta^*) = \begin{bmatrix} -(\mu + p_1) & 0 & 0 & 0 & K_1 & K_4 \\ p_1 & -(\mu + \alpha p_2) & 0 & 0 & K_2 & K_5 \\ 0 & \alpha p_2 & -\mu & 0 & K_3 & K_6 \\ 0 & 0 & 0 & -(\mu + e) & H_1^* & H_2^* \\ 0 & 0 & 0 & \rho e & -(\mu + r_a) & 0 \\ 0 & 0 & 0 & (1 - \rho)e & 0 & -(r_s + \mu + d + \delta) \end{bmatrix},$$

where

$$\begin{aligned} K_1 &= S^* \frac{\partial h}{\partial I_a}(E_v, \beta^*) \\ K_2 &= -(1 - \eta_1)V_1^* \frac{\partial h}{\partial I_a}(E_v, \beta^*) \\ K_3 &= -(1 - \eta_2)V_2^* \frac{\partial h}{\partial I_a}(E_v, \beta^*) \\ K_4 &= S^* \frac{\partial h}{\partial I_s}(E_v, \beta^*) \\ K_5 &= -(1 - \eta_1)V_1^* \frac{\partial h}{\partial I_s}(E_v, \beta^*) \\ K_6 &= -(1 - \eta_2)V_2^* \frac{\partial h}{\partial I_s}(E_v, \beta^*) \\ H_1^* &= \beta^* \tau \frac{\mu(\mu + \alpha p_2) + \mu(1 - \eta_1)p_1 + (1 - \eta_2)p_1 p_2 \alpha}{(p_1 + \mu)(\mu + \alpha p_2)} \\ H_2^* &= \beta^* \frac{\mu(\mu + \alpha p_2) + \mu(1 - \eta_1)p_1 + (1 - \eta_2)p_1 p_2 \alpha}{(p_1 + \mu)(\mu + \alpha p_2)} \end{aligned}$$

We observed that one of the eigenvalues of $J(E_v, \beta^*)$ is 0 and the remaining are negative. Hence, when $\beta = \beta^*$ (equivalently, when $R_v = 1$), the disease-free equilibrium is nonhyperbolic.

After some calculations we get:

$$\nu = (0, 0, 0, \nu_4, \frac{\nu_4 H_1^*}{\mu + r_a}, \frac{\nu_4 H_2^*}{r_s + \mu + d + \delta}) \quad \text{and} \quad \omega = (\omega_1, \omega_2, \omega_3, 1, \frac{e\rho}{\mu + r_a}, \frac{e(1 - \rho)}{r_s + \mu + d + \delta})^T,$$

where

$$\begin{aligned} \nu_4 &= \frac{(\mu + r_a)^2 (r_s + \mu + d + \delta)^2}{(\mu + r_a)^2 (r_s + \mu + d + \delta)^2 + H_1^* e \rho (r_s + \mu + d + \delta)^2 + H_2^* e (1 - \rho) (\mu + r_a)^2} \\ \omega_1 &= \frac{K_1 e \rho (r_s + \mu + d + \delta) + K_4 e (1 - \rho) (\mu + r_a)}{(\mu + p_1) (\mu + r_a) (r_s + \mu + d + \delta)} < 0 \\ \omega_2 &= \frac{p_1 \omega_1 (\mu + r_a) (r_s + \mu + d + \delta) + K_2 e \rho (r_s + \mu + d + \delta) + K_5 e (1 - \rho) (\mu + r_a)}{(\mu + \alpha p_2) (\mu + r_a) (r_s + \mu + d + \delta)} < 0 \\ \omega_3 &= \frac{p_2 \alpha \omega_2 \mu (\mu + r_a) (r_s + \mu + d + \delta) + K_3 e \rho (r_s + \mu + d + \delta) + K_6 e (1 - \rho) (\mu + r_a)}{\mu (\mu + r_a) (r_s + \mu + d + \delta)} < 0. \end{aligned}$$

are a left and right eigenvector associated with the zero eigenvalue, respectively, such that $\nu \cdot \omega = 1$. Now we can explicitly compute the coefficients a and b . Considering only the nonzero components of the eigenvectors and computing the corresponding second derivative of f , it follows that:

$$\begin{aligned}
 a &= \sum_{k,i,j=1}^6 \nu_k \omega_i \omega_j \frac{\partial^2 f_k}{\partial x_i \partial x_j}(E_v, \beta^*) \\
 &= 2[\nu_4 \omega_1 (\omega_5 \frac{\partial^2 f_4}{\partial S \partial I_a}(E_v, \beta^*) + \omega_6 \frac{\partial^2 f_4}{\partial S \partial I_s}(E_v, \beta^*)) + \nu_4 \omega_2 (\omega_5 \frac{\partial^2 f_4}{\partial V_1 \partial I_a}(E_v, \beta^*) + \omega_6 \frac{\partial^2 f_4}{\partial V_1 \partial I_s}(E_v, \beta^*)) \\
 &\quad + \nu_4 \omega_3 (\omega_5 \frac{\partial^2 f_4}{\partial V_2 \partial I_a}(E_v, \beta^*) + \omega_6 \frac{\partial^2 f_4}{\partial V_2 \partial I_s}(E_v, \beta^*))] \\
 &= \frac{2\beta^*}{(\mu + r_a)(r_s + \mu + d + \delta)} \left[e\omega_1 (\tau\rho(r_s + \mu + d + \delta) + (1 - \rho)(\mu + r_a)) \right. \\
 &\quad + e\omega_2 (\rho\tau(1 - \eta_1)(r_s + \mu + d + \delta) + (1 - \rho)(1 - \eta_1)(\mu + r_a)) \\
 &\quad \left. + e\omega_3 (\rho\tau(1 - \eta_2)(r_s + \mu + d + \delta) + (1 - \rho)(1 - \eta_2)(\mu + r_a)) \right]
 \end{aligned}$$

Since ω_1, ω_2 and ω_3 are negative, $a < 0$.

And

$$\begin{aligned}
 b &= \sum_{k,i=1}^6 \nu_k \omega_i \frac{\partial^2 f_k}{\partial x_i \partial \beta}(E_v, \beta^*) \\
 &= \nu_4 \left[\omega_2 \frac{\partial^2 f_4}{\partial V_1 \partial \beta}(E_v, \beta^*) + \omega_2 \frac{\partial^2 f_4}{\partial V_2 \partial \beta}(E_v, \beta^*) + \omega_2 \frac{\partial^2 f_4}{\partial I_a \partial \beta}(E_v, \beta^*) + \omega_2 \frac{\partial^2 f_4}{\partial I_s \partial \beta}(E_v, \beta^*) \right] \\
 &= \nu_4 \left[\frac{e\rho\tau}{\mu + r_a} (S^* + (1 - \eta_1)V_1^* + (1 - \eta_2)V_2^*) + \frac{e(1 - \rho)}{r_s + \mu + d + \delta} (S^* + (1 - \eta_2)V_1^* + (1 - \eta_2)V_2^*) \right] \\
 &= \nu_4 (S^* + (1 - \eta_1)V_1^* + (1 - \eta_2)V_2^*) \left[\frac{e\rho\tau}{\mu + r_a} + \frac{e(1 - \rho)}{r_s + \mu + d + \delta} \right] > 0
 \end{aligned}$$

226 Since $a < 0$ and $b > 0$, by the result of Castillo-Chavez and Song [6], model (17) exhibits a forward bifurcation
 227 at $R_v = 1$ (see Figure 5). We summarize the above discussion with the following theorem.

228 **Theorem 3.3.1.** *The endemic equilibrium point, E_{dfe} of the model system (17), is locally asymptotically*
 229 *stable for $R_v > 1$ and the system exhibits forward (or transcritical) bifurcation at $R_v = 1$.*

230 3.4 Sensitivity analysis

231 In what follows, we investigate the sensitivity analysis for the control reproduction number R_v to identify the
 232 parameters that has high impact on disease expansion in the community. The sensitivity index with respect
 233 to a parameter X_i is given by a normalized forward sensitivity index [8],

$$234 \quad \Gamma_{X_i}^{R_v} = \frac{\partial R_v}{\partial X_i} \times \frac{X_i}{R_v},$$

where, X_i represent the basic parameters.

Hence,

$$\begin{aligned} \Gamma_e^{R_v} &= \frac{\partial R_v}{\partial e} \times \frac{e}{R_v} = \frac{\mu}{\mu + e} > 0, \\ \Gamma_{\eta_1}^{R_v} &= \frac{\partial R_v}{\partial \eta_1} \times \frac{\eta_1}{R_v} = -\frac{p_1 \mu}{(\mu + e)(\mu + p_1)(\mu + \alpha p_2)} \left(\frac{\rho e \beta \tau}{\mu + r_a} + \frac{(1 - \rho)e\beta}{r_s + \mu + d + \delta} \right) \times \frac{\eta_1}{R_v} < 0, \\ \Gamma_{\eta_2}^{R_v} &= \frac{\partial R_v}{\partial \eta_2} \times \frac{\eta_2}{R_v} = -\frac{\alpha p_1 p_2}{(\mu + e)(\mu + p_1)(\mu + \alpha p_2)} \left(\frac{\rho e \beta \tau}{\mu + r_a} + \frac{(1 - \rho)e\beta}{r_s + \mu + d + \delta} \right) \times \frac{\eta_2}{R_v} < 0, \\ \Gamma_{p_1}^{R_v} &= \frac{\partial R_v}{\partial p_1} \times \frac{p_1}{R_v} = -\frac{(\mu^2 \eta_1 + \alpha \eta p_2 \eta_2)}{(\mu + e)(\mu + p_1)^2 (\mu + \alpha p_2)} \left(\frac{\rho e \beta \tau}{\mu + r_a} + \frac{(1 - \rho)e\beta}{r_s + \mu + d + \delta} \right) \times \frac{p_1}{R_v} < 0, \\ \Gamma_{p_2}^{R_v} &= \frac{\partial R_v}{\partial p_2} \times \frac{p_2}{R_v} = -\frac{\alpha^2 p_2 (1 - \mu)}{(\mu + e)(\mu + p_1)(\mu + \alpha p_2)^2} \left(\frac{\rho e \beta \tau}{\mu + r_a} + \frac{(1 - \rho)e\beta}{r_s + \mu + d + \delta} \right) \times \frac{p_2}{R_v} < 0, \\ \Gamma_{\alpha}^{R_v} &= \frac{\partial R_v}{\partial \alpha} \times \frac{\alpha}{R_v} = \frac{\mu p_1 p_2 (\eta_1 - \eta_2)}{(\mu + e)(\mu + p_1)(\mu + \alpha p_2)^2} \left(\frac{\rho e \beta \tau}{\mu + r_a} + \frac{(1 - \rho)e\beta}{r_s + \mu + d + \delta} \right) \times \frac{\alpha}{R_v} < 0, \\ \Gamma_{\beta}^{R_v} &= \frac{\partial R_v}{\partial \beta} \times \frac{\beta}{R_v} = 1 > 0, \\ \Gamma_{\tau}^{R_v} &= \frac{\partial R_v}{\partial \tau} \times \frac{\tau}{R_v} = \frac{(\mu(\mu + \alpha p_2) + \mu p_1(1 - \eta_1) + \alpha p_1 p_2)(\rho e \beta)}{(\mu + e)(\mu + p_1)(\mu + \alpha p_2)(\mu + r_a)} \times \frac{\tau}{R_v} > 0, \\ \Gamma_{r_a}^{R_v} &= \frac{\partial R_v}{\partial r_a} \times \frac{r_a}{R_v} = -\frac{(\mu(\mu + \alpha p_2) + \mu p_1(1 - \eta_1) + \alpha p_1 p_2)(\rho e \beta \tau)}{(\mu + e)(\mu + p_1)(\mu + \alpha p_2)(\mu + r_a)^2} \times \frac{r_a}{R_v} < 0, \\ \Gamma_{r_s}^{R_v} &= \frac{\partial R_v}{\partial r_s} \times \frac{r_s}{R_v} = -\frac{(\mu(\mu + \alpha p_2) + \mu p_1(1 - \eta_1) + \alpha p_1 p_2)((1 - \rho)e\beta)}{(\mu + e)(\mu + p_1)(\mu + \alpha p_2)(r_s + \mu + d + \delta)^2} \times \frac{r_s}{R_v} < 0, \\ \Gamma_{\delta}^{R_v} &= \frac{\partial R_v}{\partial \delta} \times \frac{\delta}{R_v} = -\frac{(\mu(\mu + \alpha p_2) + \mu p_1(1 - \eta_1) + \alpha p_1 p_2)((1 - \rho)e\beta)}{(\mu + e)(\mu + p_1)(\mu + \alpha p_2)(r_s + \mu + d + \delta)^2} \times \frac{\delta}{R_v} < 0, \\ \Gamma_d^{R_v} &= \frac{\partial R_v}{\partial d} \times \frac{d}{R_v} = -\frac{(\mu(\mu + \alpha p_2) + \mu p_1(1 - \eta_1) + \alpha p_1 p_2)((1 - \rho)e\beta)}{(\mu + e)(\mu + p_1)(\mu + \alpha p_2)(r_s + \mu + d + \delta)^2} \times \frac{d}{R_v} < 0. \end{aligned}$$

235 We summarize the sensitivity analysis indices of the reproduction number with respect to some parameters
236 in Table 1.

parameter	index
e	+ve
β	+ve
τ	+ve
η_1	-ve
η_2	-ve
p_1	-ve
p_2	-ve
α	-ve
r_a	-ve
r_s	-ve
δ	-ve
d	-ve

Table 1: Sensitivity index table

237 From Table1 the sensitivity indices with negative signs indicate that the value of R_v decreases when the
238 parameter values are increased and the value of R_v increases when the parameter values are decreased, while
239 sensitivity indices with positive signs indicate that the value of R_v increases when the parameter values are
240 increased and the value of R_v decreases when the parameter values are decreased.

241 4. Numerical simulation and discussion

242 To justify the analytical results and explore additional important properties of the model, we fitted the model
 243 to real COVID-19 data of Ethiopia to fix the unknown parameters of the model and carried out a numerical
 244 simulation. In this section, we used the full model (2).

245 4.1 Parameter estimation

246 In this subsection, we will find the best values of unknown parameters in our model, with the so-called
 247 model fitting process. We used the real data of COVID-19 daily new cases and vaccinated population of
 248 Ethiopia from May 01, 2021 to January 31, 2022. We took the data which is available online by Our World in
 249 Data [19]. To fit the model to this data, we used the nonlinear curve fitting method with the help of
 250 'lsqcurvefit', builtin MATLAB function. Some of the parameter values are estimated from literature:
 251 according to the data by Worldometer, the Ethiopian average life expectancy at birth for the year 2021 and
 252 the approximate total population is 67.8 and 114963588 respectively [27]. Therefore, the natural death rate
 253 of individuals per day is calculated as the reciprocal of the life expectancy at birth time days in a year, given
 254 by $\mu = \frac{1}{67.8 \times 365}$. We approximated the recruitment rate from $\frac{\pi}{\mu} = N(0)$ (Initial population). Hence we found
 255 $\pi = \mu \times N(0) = 4646$ individuals per day. In the estimation process of the rest parameters the following
 256 initial conditions are used: from the data in Our World in Data we have
 257 $I_s(0) = 620, V_1(0) = 20385, R(0) = 946$ and $D(0) = 21$. Where $t = 0$ corresponds to May 01, 2021. According
 258 to WHO report 80% of COVID-19 infected individuals become asymptomatic. Therefore we estimated
 259 $I_a(0) = 620/0.8 = 775$. We assumed $E(0) = 1400$, which is approximately equal to the sum of the
 260 symptomatic and asymptomatic cases, and $V_1(0) = Q(0) = H(0) = 0$. Hence, the initial susceptible
 261 population is taken as $S(0) = N(0) - (V_1(0) + V_2(0) + E(0) + I_a(0) + I_s(0) + Q(0) + H(0) + R(0))$.

262
 263 The best fit to the daily cumulative COVID-19 confirmed cases and vaccination through our model is shown
 264 in Figure 2. The estimated and calculated parameter values are given in Table 2. Using these parameters,
 265 we found $R_0 = 1.17$ and $R_v = 1.15$.




Figure 2: The fitted data to the reported cumulative cases (panel (a)) and cumulative vaccinated (panel (b)) using the model (2) for Ethiopia from May 01, 2021 to January 31, 2022.

Parameter	Description	Value	Sources
π	Recruitment rate	4646 days^{-1}	Calculated Sec.4.1
μ	Natural death rate	$\frac{1}{67.8 \times 365}$	Calculated Sec.4.1
p_1	First dose Vaccination rate	$8.157 \times 10^{-7} \text{ days}^{-1}$	Fitted
p_2	Second dose Vaccination rate	0.974 days^{-1}	Fitted
β	Transmission rate	0.513 days^{-1}	Fitted
τ	Infectivity factor for asymptomatic individuals	0.116	Fitted
η_1	Efficacy of first dose vaccine	0.8	Fitted
η_2	Efficacy of second dose vaccine	0.95	Fitted
α	Inverse of average time needed to take the second dose	0.14 days^{-1}	Fitted
ρ	fraction of infections that become asymptomatic	0.112	Fitted
e	Infection rate after incubation period	0.2071	Fitted
r_s	Recovery rate for individuals with symptom	$1.89 \times 10^{-7} \text{ days}^{-1}$	Fitted
r_a	Recovery rate for asymptomatic individuals	0.0148 days^{-1}	Fitted
r_q	Recovery rate for quarantined individuals	0.0356 days^{-1}	Fitted
r_h	Recovery rate for individuals in hospital	0.213 days^{-1}	Fitted
δ	Quarantine rate	0.453 days^{-1}	Fitted
d	Disease induced death rate	0.177 days^{-1}	Fitted
q_h	Hospitalization rate from quarantine	0.999 days^{-1}	Fitted

Table 2: Parameter description and their baseline values used in the model (2).

266 4.2 Local stability of disease-free and endemic equilibrium

267 Figure 3, panels (a) and (b) (for time interval [9000, 30000]) shows the local stability of the endemic equilibrium
268 $E_{end} = [3.77 \times 10^{-7}, 225, 6.91 \times 10^5, 1.49 \times 10^4, 2.334 \times 10^4, 4.36 \times 10^3, 1.632 \times 10^3, 4.181 \times 10^3, 3.201 \times 10^7]$
269 for $R_v = 2.98 > 1$. Panels (c) and (d) portrays the stability of the disease free equilibrium, $E_{dfe} = [1.127 \times$
270 $10^8, 673.9, 2.2741 \times 10^6, 0, 0, 0, 0, 0, 0]$, for $R_v = 0.556 < 1$. These results support our analytical results in
271 section 3 of Theorem 3.2.2 and 3.3.1. For better use of spacing and view we didn't include the plot for E
272 compartment, but the dynamics of this state variable converges to its equilibrium point. The convergence
273 to the endemic equilibrium is through damped oscillation, which may show the disease will be endemic in
274 different times in the future. When $R_v = 1$ an exchange of stability (transcritical bifurcation) arises, *i.e.*
275 for $R_v < 1$ there is no endemic equilibrium and the disease-free equilibrium is globally asymptotically stable
276 and for $R_v > 1$ a stable endemic equilibrium appears whereas the disease-free equilibrium is unstable. This
277 property is shown in Figure 5. From an epidemiological point of view, this means the disease may persist in
278 the population for $R_v > 1$ and dies out for $R_v < 1$.

279 **Remark 3.** In Figure 3, panels (a) and (b) at the beginning of the interval (*i.e.*, [0, 9000]) there is a relatively
280 high peak, therefore in the plot with full interval the MATLAB suppresses the other peaks. Therefore, for
281 better visualization of the long time interval behaviour of the model, we put the plot only for the interval
282 [9000, 300000].




Figure 3: Local stability of the endemic equilibrium for $R_v = 2.98 > 1$ (infected compartments, panels (a), and non infected compartments, panel (b)) and local stability of the disease free equilibrium for $R_v = 0.556 < 1$ (infected compartments, panel (c), and non infected compartments, panel (d).) $\tau_1 = 0.6$ and $p_1 = 5 \times 10^{-5}$ is used for panels (a)&(b) and (c)&(d) respectively and other parameter values are given in Table 2.

283 4.3 Variation of R_v with respect to some important parameters

284 An important parameter in modeling infectious disease transmission is the reproduction parameter which
 285 measures the potential spread of an infectious disease in a community, in our case we have a control
 286 reproduction parameter, R_v . In particular, if $R_v < 1$ the disease dies out and if $R_v > 1$ the disease persists
 287 in the population. Therefore reducing such parameter below the critical value $R_v = 1$ is important. In our
 288 model, reducing the transmission rate β and infectivity factor of asymptomatic individuals, τ will help
 289 reduce R_v from unity, Figure 4 panels (a) and (b). On the contrary increasing the first dose vaccination rate,
 290 p_1 will make R_v less than one, Figure 4 panel (c). Here it is worth to mention the influence of the second
 291 dose vaccination rate is low in varying the control reproduction number.




Figure 4: Variation of R_v with respect to : the transmission rate β ,panel (a), to infectivity factor of asymptomatic individuals τ , panel (b) and first dose vaccination rate p_1 , panel (c). Other parameter values are given in Table 2.




Figure 5: Transcritical bifurcation of model (2) when $R_v = 1$.

292 4.4 The impact of transmission rate

293 In this and subsequent subsections, we say infectious population to refer to the sum of the population in
 294 symptomatic and asymptomatic classes per time ($I_a(t) + I_s(t)$). This is due to the fact that in our model
 295 we assumed people in these two compartments are potential transmitters of the disease. Unless explicitly
 296 mentioned, when we say vaccinated individuals, it refers to the total number of individuals vaccinated either
 297 with the first dose or the second dose per unit time ($V_1(t) + V_2(t)$). Figure 6 shows the role of the transmission
 298 rate β on the dynamics of the infectious, vaccinated, and hospitalized classes. A decrease in the transmission
 299 rate results in a prevalence decrease. When the transmission rate is equal to 0.55 days^{-1} the prevalence reaches
 300 a high peak of 1424101, but by decreasing it to $\beta = 0.49 \text{ days}^{-1}$ (below the fitted value) the infectious peak
 301 can be decreased to 410094 Figure 6 panel (a). This shows that if we can further decrease the transmission
 302 rate, it is possible to achieve an infectious number of insignificant value and eradication of the disease. When
 303 the transmission rate is small, a small number of people will be infected, which means the number of people
 304 in the susceptible class will be large, hence the number of vaccinated people will rise, Figure 6, panel(b). The
 305 burden of hospitalization can be decreased by decreasing the transmission rate. As it can be seen in Figure
 306 6, panel(c), when the infectious population is high, correspondingly we have a large number of individuals in
 307 the hospital and vice versa.




Figure 6: The effect of transmission rate β . Panel (a): infectious population $I_a(t) + I_s(t)$, panel (b): Vaccinated population, $V_1(t) + V_2(t)$, and panel (c) hospitalized individuals. Other parameter values are given in the Table 2.

308 4.5 The impact of first dose vaccination rate

309 Figure 7 shows the role of the first dose vaccination rate on the dynamics of infectious, vaccinated and
 310 hospitalized population. Increasing this vaccination rate results in a decrease of infectious and hospitalized
 311 population Figure 7 panels (a)&(c). For example when $p_1 = 8.16 \times 10^{-7} \text{ days}^{-1}$ the infectious population
 312 reaches a high peak of value 759544 and hospitalized peak of 118624 individuals. If we are able to increase
 313 the rate to $p_1 = 8.16 \times 10^{-5} \text{ days}^{-1}$ the above peaks will decrease to 171226 and 26151 of infectious and
 314 hospitalized individuals respectively. Such a decrease in prevalence is achieved with high proportion of
 315 vaccinated individuals in the population Figure 7 panel (b). Simulation results shows that the role of the
 316 second dose vaccination rate, p_2 and time delay between the two doses, α doesn't have significant impact on
 317 the dynamics.




Figure 7: The impact of the first dose vaccination rate p_1 : on the dynamics of infectious population,panel (a),
 vaccinated population, panel (b), and hospitalized population, panel (c). Other parameter values are given in the Table
 2.

318 4.6 The impact of the infectivity factor of asymptomatic individuals

319 According to the study [22], asymptomatic cases of COVID-19 are a potential source of substantial spread
 320 of the disease within the community and one of the results found was people with asymptomatic COVID-19
 321 are infectious but might be less infectious than symptomatic cases. Since the majority of COVID-19 infected
 322 individuals become asymptomatic, even if they are less infectious than the symptomatic individuals, their role
 323 in spreading the disease may be significant. Figure 8 proves this hypothesis. As the infectivity factor increases,
 324 we observed a rise of the infectious population to a relatively high pick (2799983 infectious for $\tau = 0.2$) Figure
 325 8, panel (a), which is not observed in the impact of other parameters, like β . Decreasing the infectivity factor

326 decreases the infectious population significantly. As observed in other plots here also the increase of infectious
 327 population will result in increase in the number of hospitalized individuals and vice versa Figure 8 panel (c).
 328 The increase in the infectivity factor τ makes more people to be infected from vaccinated compartments which
 329 results in a decrease in the number of vaccinated individuals, Figure 8 panel (b). Therefore the number of
 330 vaccinated individuals is inversely proportional to the infectivity factor.




Figure 8: The impact of the infectivity coefficient of asymptomatic population, τ_1 on the dynamics of infectious population, panel (a), total vaccinated population, panel (b), and hospitalized population, panel (c). Other parameter values are as in the Table (2).

331 5. Prediction of cumulative vaccine dose administered with respect to 332 the first dose vaccination rate.

333 Most of COVID-19 vaccines approved by WHO are being offered in two doses and a booster. In Ethiopia
 334 Sinopharm, AstraZeneca, Johnson and Johnson/Janssen, and Pfizer-BioNTech vaccines are being used. From
 335 these vaccines except Johnson&Johnson/Janssen all are being given in two doses. The total number of
 336 COVID-19 vaccine dose administered from May 01, 2021 to January 31, 2022 (276 days) is 9517539. Using
 337 the fitted parameters, our model estimates this number by 9152542 vaccine doses (See, the highlighted row
 338 third column of Table 3). If the first dose vaccine administration rate remains the same for the next two
 339 years, (*i.e* after 1006 days) 66483093 number of vaccine doses will be administered. According to World
 340 Population Review projection, Ethiopian population in 2024 will be 126.8 million [26]. Since a person can
 341 get vaccinated with two doses, we can approximate the number of people vaccinated with at least one dose
 342 by $\frac{1}{2} \times$ number of vaccine dose administered. This means 33241546 number of people (Approximately 26%
 343 of the total population (in 2024)) will get at least one dose of COVID-19 vaccination. Increasing p_1 to
 344 $3.16 \times 10^{-6} \text{ days}^{-1}$ it can be achieved, after two years, 199688874 number of administered vaccine doses.
 345 Which is equivalent to 99844437 number of people (approximately 79% of the total population in the year
 346 2024) can get at least first dose (see fourth row of Table 3).

p_1	R_v	Vaccine dose administered in $[0, 276]$ days (Interval of fitting time)	Predicted after two years ($[0, 1006]$ days interval)
$8.157 \times 10^{-7} \text{ days}^{-1}$	1.15	9152542	66483093
$9.16 \times 10^{-7} \text{ days}^{-1}$	1.147	9588497	72169187
$1.16 \times 10^{-6} \text{ days}^{-1}$	1.141	10652193	86042042
$3.16 \times 10^{-6} \text{ days}^{-1}$	1.09	19369216	199688874

Table 3: Values of: Control reproduction number (second column), cumulative vaccine administered at the end of the parameter fitting time (third column) and Predicted number of cumulative vaccine to be administered (fourth column). For different values of p_1 . Other parameter values are given in Table 2. The light Cyan shaded row is for the base line p_1 value.

6. Conclusion

In this study, we used a compartmental model for COVID-19 transmission with vaccination. We divided the vaccinated portion of the population into two: Vaccinated with the first dose and fully vaccinated (those who got the two doses). Using the next generation matrix we found a reproduction number which exists when vaccination is in place, we called this parameter as the control reproduction number and denoted it by R_v . We calculated the disease-free and endemic equilibrium of model (2) and showed that the disease-free equilibrium E_{df_e} is globally asymptotically stable if the control reproduction number $R_v < 1$ and unstable if $R_v > 1$. We performed a center manifold analysis based on the method mentioned in Castillo-Chavez and Song[6] and found that the model exhibits a forward bifurcation at $R_v = 1$, which ensures the nonexistence of the endemic equilibrium below the critical value, $R_v = 1$ and the unique endemic equilibrium which exists for $R_v > 1$ is locally asymptotically stable. This implies the disease can be controlled if $R_v < 1$ and it persists in the population if $R_v > 1$. This directs public health policy makers to work on reducing the control reproduction number to less than unity. We performed a sensitivity analysis from which we obtained that the model is sensitive to p_1, p_2, δ with negative sign and β, τ with positive sign. This shows that increasing the vaccination and quarantine rate and decreasing the transmission rate and infectivity factor of asymptomatic individuals will reduce the disease burden.

We performed model fitting to the Ethiopian real COVID-19 data for the period from May 1, 2021 to January 31, 2022 to estimate the unknown parameters in the model. In the numerical simulation section, we support our analytical analysis about the stability of the disease-free and endemic equilibrium using the parameter R_v . The result shows for $R_v > 1$ the endemic equilibrium (which exists only for $R_v > 1$) stabilizes through damped oscillation and the disease-free equilibrium is locally asymptotically stable $R_v < 1$, unstable for $R_v > 1$. From the epidemiological perspective, the disease persists in the population with multiple waves if the control reproduction number is greater than unity and it can be eliminated if $R_v < 1$. We also showed the role of some important parameters on the dynamics of the disease so that we got the following points: Reducing the transmission rate and the infectivity factor of asymptomatic individuals will greatly help in reducing the infection burden. Increasing the first dose vaccination rate has a high impact in reducing the infection. Simulation results shows that the second dose vaccination rate has no significant effect on the dynamics of the infectious population.

Moreover, we also predicted the cumulative vaccine dose administered by changing the first dose vaccination rate. In this prediction, if we increase p_1 to a value $3.16 \times 10^{-7} \text{ days}^{-1}$ after two years, the total vaccine dose administered will reach 1996888974, which will cover approximately 79% of the total population. Therefore, from the numerical simulation and analytical analysis, we summarize that it will be essential to reduce the transmission rate, infectivity factor of asymptomatic cases and increase the vaccination rate, quarantine rate to control the disease. As a future work, we will point out that this model can be extended by including additional interventions (for example nonpharmaceutical interventions), by considering the

384 behavioural aspect, and via an optimal control problems.

385 **Data Availability**

386 Data will be available on request.

387 **Conflict of Interest**

388 The Authors declare that they have no conflicts of interest.

389

References

- [1] M. A. Acuña-Zegarra, M. Santana-Cibrian, and J. X. Velasco-Hernandez. Modeling behavioral change and covid-19 containment in mexico: A trade-off between lockdown and compliance. *Mathematical biosciences*, 325:108370, 2020.
- [2] V. P. Bajiya, S. Bugalia, and J. P. Tripathi. Mathematical modeling of covid-19: impact of non-pharmaceutical interventions in india. *Chaos: An Interdisciplinary Journal of Nonlinear Science*, 30(11):113143, 2020.
- [3] Y. Bo, C. Guo, C. Lin, Y. Zeng, H. B. Li, Y. Zhang, M. S. Hossain, J. W. Chan, D. W. Yeung, K. O. Kwok, et al. Effectiveness of non-pharmaceutical interventions on covid-19 transmission in 190 countries from 23 january to 13 april 2020. *International Journal of Infectious Diseases*, 102:247–253, 2021.
- [4] B. Buonomo and R. Della Marca. Effects of information-induced behavioural changes during the covid-19 lockdowns: the case of italy. *Royal Society open science*, 7(10):201635, 2020.
- [5] B. Buonomo, R. Della Marca, A. d’Onofrio, and M. Groppi. A behavioural modelling approach to assess the impact of covid-19 vaccine hesitancy. *arXiv preprint arXiv:2106.11745*, 2021.
- [6] C. Castillo-Chavez and B. Song. Dynamical models of tuberculosis and their applications. *Mathematical Biosciences & Engineering*, 1(2):361, 2004.
- [7] C. C. Chavez, Z. Feng, and W. Huang. On the computation of r_0 and its role on global stability. *Mathematical Approaches for Emerging and Re-emerging Infection Diseases: An Introduction*, 125:31–65, 2002.
- [8] N. Chitnis, J. M. Hyman, and J. M. Cushing. Determining important parameters in the spread of malaria through the sensitivity analysis of a mathematical model. *Bulletin of mathematical biology*, 70(5):1272, 2008.
- [9] P. Das, R. K. Upadhyay, A. K. Misra, F. A. Rihan, P. Das, and D. Ghosh. Mathematical model of covid-19 with comorbidity and controlling using non-pharmaceutical interventions and vaccination. *Nonlinear Dynamics*, pages 1–15, 2021.
- [10] C. T. Deressa and G. F. Duressa. Modeling and optimal control analysis of transmission dynamics of covid-19: the case of ethiopia. *Alexandria Engineering Journal*, 60(1):719–732, 2021.
- [11] O. Diekmann and J. A. P. Heesterbeek. *Mathematical epidemiology of infectious diseases: model building, analysis and interpretation*, volume 5. John Wiley & Sons, 2000.
- [12] O. Diekmann, J. A. P. Heesterbeek, and J. A. Metz. On the definition and the computation of the basic reproduction ratio r_0 in models for infectious diseases in heterogeneous populations. *Journal of mathematical biology*, 28(4):365–382, 1990.
- [13] S. E. Eikenberry, M. Mancuso, E. Iboi, T. Phan, K. Eikenberry, Y. Kuang, E. Kostelich, and A. B. Gumel. To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the covid-19 pandemic. *Infectious Disease Modelling*, 5:293–308, 2020.

- [14] B. A. Ejigu, M. D. Asfaw, L. Cavalerie, T. Abebaw, M. Nanyingi, and M. Baylis. Assessing the impact of non-pharmaceutical interventions (npi) on the dynamics of covid-19: A mathematical modelling study of the case of ethiopia. *PloS one*, 16(11):e0259874, 2021.
- [15] Z. S. Kifle and L. L. Obsu. Mathematical modeling for covid-19 transmission dynamics: A case study in ethiopia. *Results in Physics*, page 105191, 2022.
- [16] K. G. Mekonen, T. G. Habtemicheal, and S. F. Balcha. Modeling the effect of contaminated objects for the transmission dynamics of covid-19 pandemic with self protection behavior changes. *Results in Applied Mathematics*, 9:100134, 2021.
- [17] S. Moore, E. M. Hill, M. J. Tildesley, L. Dyson, and M. J. Keeling. Vaccination and non-pharmaceutical interventions for covid-19: a mathematical modelling study. *The Lancet Infectious Diseases*, 21(6):793–802, 2021.
- [18] C. N. Ngonghala, E. Iboi, S. Eikenberry, M. Scotch, C. R. MacIntyre, M. H. Bonds, and A. B. Gumel. Mathematical assessment of the impact of non-pharmaceutical interventions on curtailing the 2019 novel coronavirus. *Mathematical biosciences*, 325:108364, 2020.
- [19] Our World in Data. Ethiopia: Coronavirus pandemic country profile. <https://ourworldindata.org/coronavirus/country/ethiopia>, 2021. (Accessed on Feb 05, 2022).
- [20] T. A. Perkins and G. España. Optimal control of the covid-19 pandemic with non-pharmaceutical interventions. *Bulletin of Mathematical Biology*, 82(9):1–24, 2020.
- [21] H. Ritchie, E. Mathieu, L. Rodés-Guirao, C. Appel, C. Giattino, E. Ortiz-Ospina, J. H. B. Macdonald, D. Beltekian, and M. Roser. Coronavirus pandemic (covid-19). *Our World in Data*, 2021. <https://ourworldindata.org/covid-vaccinations>.
- [22] A. A. Sayampanathan, C. S. Heng, P. H. Pin, J. Pang, T. Y. Leong, and V. J. Lee. Infectivity of asymptomatic versus symptomatic covid-19. *The Lancet*, 397(10269):93–94, 2021.
- [23] A. Ssematimba, J. Nakakawa, J. Ssebuliba, and J. Y. Mugisha. Mathematical model for covid-19 management in crowded settlements and high-activity areas. *International Journal of Dynamics and Control*, pages 1–12, 2021.
- [24] WHO. 10 vaccines granted emergency use listing (eul) by who. <https://covid19.trackvaccines.org/agency/who/>, 2022. (Accessed on March 09, 2022).
- [25] WHO. Who coronavirus (covid-19) dashboard. <https://covid19.who.int/>, 2022. (Accessed on March 09, 2022).
- [26] World Population Review. Ethiopia population projections. <https://worldpopulationreview.com/countries/ethiopia-population>, 2022. (Accessed on March 08, 2022).
- [27] Worldometer. Ethiopia demographics. <https://www.worldometers.info/demographics/ethiopia-demographics/>, 2021. (Accessed on Feb 05, 2022).